공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

혈구탐식성 림프조직구증(HLH) : 주요 14개 시장 예측

Epiomic Epidemiology Series: Haemophagocytic lymphohistiocytosis (HLH) Forecast in 14 Major Markets 2016-2026

리서치사 Black Swan Analysis
발행일 2016년 10월 상품 코드 403741
페이지 정보 영문 52 Pages
가격
US $ 4,250 ₩ 4,752,000 PDF (Single User License)
US $ 6,400 ₩ 7,156,000 PDF (Site License/Up to 5 Users)
US $ 7,700 ₩ 8,610,000 PDF (Corporate License)


혈구탐식성 림프조직구증(HLH) : 주요 14개 시장 예측 Epiomic Epidemiology Series: Haemophagocytic lymphohistiocytosis (HLH) Forecast in 14 Major Markets 2016-2026
발행일 : 2016년 10월 페이지 정보 : 영문 52 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 14개국(브라질, 캐나다, 덴마크, 핀란드, 프랑스, 독일, 이탈리아, 일본, 네덜란드, 노르웨이, 스페인, 스웨덴, 영국, 미국)의 혈구탐식성 림프조직구증(HLH : Haemophagocytic Lymphohistiocytosis) 발증 상황에 대해 분석했으며, 질환 개요, 현재 유병자수, 성별·연령별(5세 단위) 상황, 지역별·민족별 동향, 위험인자, 질환 진단과 예후, 주요 증상과 합병증, 향후 동향 전망(향후 10년간) 등의 정보를 전해드립니다.

1. 서론

2. 질환의 원인

3. 위험인자와 예방법

4. 질환 진단 방법

5. 지역별/민족별 차이

6. 질환 예후와 임상 경과

7. 질환과 관련된 주요 합병증/특징

8. 환자수의 정량화 방법

9. HLH의 최대 유병자수

10. HLH의 특징

  • 혈구탐식성 림프조직구증(HLH) 분류
  • 2차성 HLH의 병인

11. HLH의 증상

  • 1차성 HLH의 증상
  • 2차성 HLH의 증상

12. 약어

13. 관련 발행물

14. 환자 기반 온라인 데이터베이스

15. 환자 기반 제품

16. 온라인 가격 데이터 및 플랫폼

17. 참고문헌

18. 부록

도표

분석 대상국

  • 브라질, 캐나다, 덴마크, 핀란드, 프랑스, 독일, 이탈리아, 일본, 네덜란드, 노르웨이, 스페인, 스웨덴, 영국, 미국
KSM 16.12.21

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Haemophagocytic lymphohistiocytosis in 14 Major Markets

Haemophagocytic lymphohistiocytosis (HLH) is an extremely rare haematological disorder. It occurs when there is an uncontrollable proliferation of hyper-activated macrophages and T-lymphocytes. The hyper-activated macrophages engulf haematopoietic cells resulting in a deregulated immune system, which in turn attacks various tissues in the body. The weakened body becomes susceptible to infection.

This report provides the current incident population for Haemophagocytic lymphohistiocytosis across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Denmark, Norway, Sweden, Finland, Netherlands, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HLH have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HLH include:

  • Autoimmune conditions
  • Leukaemia
  • Lymphomas
  • HSCT
  • Infection (especially with EBV)
  • Diabetes
  • Obesity
  • COPD
  • Heart Failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Haemophagocytic lymphohistiocytosis market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Haemophagocytic lymphohistiocytosis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Haemophagocytic lymphohistiocytosis's incident population.
  • Identify sub-populations within Haemophagocytic lymphohistiocytosis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Haemophagocytic lymphohistiocytosis disease patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for HLH
  • Features of HLH patients
    • Classification of HLH
    • Aetiology of Secondary HLH
  • Symptoms of HLH
    • Symptoms of Primary HLH
    • Symptoms of Secondary HLH
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Incidence of HLH, total (000s)
  • Incidence of HLH, males (000s)
  • Incidence of HLH, females (000s)
  • HLH patients by type, total (000s)
  • Secondary HLH patients by aetiology, total (000s)
  • Primary HLH patients with Hepatosplenomegaly, total (000s)
  • Primary HLH patients with Cytopenia, total (000s)
  • Primary HLH patients with Hypertriglyceridemia, total (000s)
  • Primary HLH patients with Hypofibrinogenemia, total (000s)
  • Primary HLH patients with Elevated Fibrin, total (000s)
  • Primary HLH patients with Decreased NK-Cell Activity, total (000s)
  • Secondary HLH patients with Hepatosplenomegaly, total (000s)
  • Secondary HLH patients with Cytopenia, total (000s)
  • Secondary HLH patients with Hypertriglyceridemia, total (000s)
  • Secondary HLH patients with Hypofibrinogenemia, total (000s)
  • Secondary HLH patients with Elevated Fibrin, total (000s)
  • Secondary HLH patients with Decreased NK-Cell Activity, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of HLH by 5-yr age cohort, males (000s)
  • USA Incidence of HLH by 5-yr age cohort, females (000s)
  • Canada Incidence of HLH by 5-yr age cohort, males (000s)
  • Canada Incidence of HLH by 5-yr age cohort, females (000s)
  • France Incidence of HLH by 5-yr age cohort, males (000s)
  • France Incidence of HLH by 5-yr age cohort, females (000s)
  • Germany Incidence of HLH by 5-yr age cohort, males (000s)
  • Germany Incidence of HLH by 5-yr age cohort, females (000s)
  • Italy Incidence of HLH by 5-yr age cohort, males (000s)
  • Italy Incidence of HLH by 5-yr age cohort, females (000s)
  • Spain Incidence of HLH by 5-yr age cohort, males (000s)
  • Spain Incidence of HLH by 5-yr age cohort, females (000s)
  • UK Incidence of HLH by 5-yr age cohort, males (000s)
  • UK Incidence of HLH by 5-yr age cohort, females (000s)
  • Denmark Incidence of HLH by 5-yr age cohort, males (000s)
  • Denmark Incidence of HLH by 5-yr age cohort, females (000s)
  • Norway Incidence of HLH by 5-yr age cohort, males (000s)
  • Norway Incidence of HLH by 5-yr age cohort, females (000s)
  • Sweden Incidence of HLH by 5-yr age cohort, males (000s)
  • Sweden Incidence of HLH by 5-yr age cohort, females (000s)
  • Finland Incidence of HLH by 5-yr age cohort, males (000s)
  • Finland Incidence of HLH by 5-yr age cohort, females (000s)
  • Netherlands Incidence of HLH by 5-yr age cohort, males (000s)
  • Netherlands Incidence of HLH by 5-yr age cohort, females (000s)
  • Brazil Incidence of HLH by 5-yr age cohort, males (000s)
  • Brazil Incidence of HLH by 5-yr age cohort, females (000s)
  • Japan Incidence of HLH by 5-yr age cohort, males (000s)
  • Japan Incidence of HLH by 5-yr age cohort, females (000s)
Back to Top
전화 문의
F A Q